Bergenbio A/S, of Bergen, Norway, said it secured a capital raise of NOK212 million (US25.4 million) in a private placement from existing shareholders, including Investinor AS and Meteva AS. The company will use the proceeds, along with existing cash, to advance its pipeline of cancer drugs, in particular lead asset BGB324, an Axl kinase inhibitor, which is in phase Ib testing in acute myeloid leukemia and in stage IIIb and stage IV non-small-cell lung cancer.